Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2CNS 1

Conditions

Breast Neoplasms 1934Neoplasms 1387Carcinoma, Non-Small-Cell Lung 1328Prostatic Neoplasms 1072Multiple Myeloma 857Leukemia, Myeloid, Acute 764Neoplasm Metastasis 693Colorectal Neoplasms 679Melanoma 671Lung Neoplasms 666Lymphoma 656Leukemia 592Lymphoma, Non-Hodgkin 588Leukemia, Lymphocytic, Chronic, B-Cell 529Ovarian Neoplasms 522Pancreatic Neoplasms 493Precursor Cell Lymphoblastic Leukemia-Lymphoma 473Recurrence 466Myelodysplastic Syndromes 422Lymphoma, Follicular 407Head and Neck Neoplasms 402Carcinoma, Renal Cell 377Glioblastoma 376Lymphoma, Large B-Cell, Diffuse 372Brain Neoplasms 371Hodgkin Disease 352Carcinoma, Hepatocellular 325Squamous Cell Carcinoma of Head and Neck 323Lymphoma, Mantle-Cell 302Sarcoma 281

Interventions

pegfilgrastim 1Sunitinib 1Paclitaxel 1Ifosfamide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Dysgerminoma × Clear all
NCT00470366 2017-11-28

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
60 enrolled 11 charts
CNSGenitourinaryGynecologic

Testicular Germ Cell Tumor, Dysgerminoma, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor

NCT00453310 2015-10-27

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
10 enrolled 6 charts
GenitourinaryGynecologic

Testicular Germ Cell Tumor, Dysgerminoma, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡